Streetbeat News

Revenues

HGTY

Hagerty, a global automotive lifestyle brand, expects its total revenue to grow by 23-27% in 2023.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:45 pm

SOPH

Sophia Genetics has reaffirmed its FY23 outlook, expecting full-year constant currency revenue growth excluding COVID-19-related revenue to be between 30% and 35%. The company also anticipates operating losses to be below 2022 levels.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:44 pm

VPG

Vishay Precision Group (VPG) has projected its Q3 net revenues to be between $85M and $95M, which is in line with the consensus estimate of $90.71M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:43 pm

SMRT

SmartRent has updated its FY23 revenue guidance from $225M-$250M to $233M-$250M, compared to the estimated $239.6M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:40 pm

ENFN

Enfusion has projected its FY23 revenue to be between $170M-$175M, which is lower than the estimated $186.5M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:39 pm

PMTS

CPI Card Group has revised its sales outlook due to a decrease in customer demand in the debit and credit segment.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:38 pm

SPY

The USA has corrected its export figures to $247.50 billion, slightly higher than the previous figure of $247.10 billion.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 12:33 pm

CNSL

Consolidated Communications has initiated a business simplification and cost savings initiative, which is estimated to result in an annualized benefit of more than $30 million starting from the second half of 2023.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:03 pm

NRGV

Energy Vault has reaffirmed its FY23 outlook, expecting revenues between $325M and $425M, compared to the estimated $377.31M. The company also anticipates an adjusted EBITDA between $(50)M and $(70)M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:39 am

HBIO

Harvard Bioscience forecasts its FY23 revenues to be between $116M-$120M, slightly below the consensus estimate of $120.76M. The company anticipates a 4% headwind from discontinued products.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:38 am